ERBB2 and breast cancer: Furthermore, whether TXNIP suppresses STAT3 signaling through IL-24 activation remains to be determined in future studies.STAT3 is an established therapeutic target due to its role in promoting tumorigenesis and its association with chemotherapy resistance in aggressive tumors such as TNBC and HER2 + BC [66, 67].